Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?

Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?

Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression re...

Full description

Bibliographic Details
Main Authors: Warren Fingrut, Wendy Davis, Eric McGinnis, Karen Dallas, Khaled Ramadan, Hayley Merkeley, Heather Leitch, Yasser Abou Mourad, Ryan D. Cassaday, Camilla Ross, Chantal Léger
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Current Oncology
Subjects:
inotuzumab ozogamicin
cd22
acute lymphoblastic leukemia
flow cytometry
immunotherapy
Online Access:https://www.mdpi.com/1718-7729/28/1/27
Description
Summary:Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO.
ISSN:1198-0052
1718-7729

Similar Items